AIMS: To determine whether the infiltrating cells in the vitreous and subretinal fluid of patients with proliferative vitreoretinopathy (PVR) express messenger RNA for various cytokines found in this condition. METHODS: The presence of mRNA coding for HPRT, IL-6, IL-1beta, IL-8, and TNFalpha was investigated in 20 vitreous and subretinal fluid (SRF) samples from patients with PVR by reverse transcriptase polymerase chain reaction (RT-PCR). 16 samples from patients with retinal detachment and macular holes were used as controls. RESULTS: HPRT was detected in all samples of PVR and in 11 (69%) control cases. Patients with PVR demonstrated mRNA for the cytokines tested more often than controls. The difference was statistically significant. CONCLUSION: The presence of mRNA encoding for IL-6, IL-1beta, IL-8, and TNFalpha is significantly detected by RT-PCR in vitreous and SRF samples of patients with PVR, indicating local production of these cytokines by vitreous and SRF cells.
AIMS: To determine whether the infiltrating cells in the vitreous and subretinal fluid of patients with proliferative vitreoretinopathy (PVR) express messenger RNA for various cytokines found in this condition. METHODS: The presence of mRNA coding for HPRT, IL-6, IL-1beta, IL-8, and TNFalpha was investigated in 20 vitreous and subretinal fluid (SRF) samples from patients with PVR by reverse transcriptase polymerase chain reaction (RT-PCR). 16 samples from patients with retinal detachment and macular holes were used as controls. RESULTS:HPRT was detected in all samples of PVR and in 11 (69%) control cases. Patients with PVR demonstrated mRNA for the cytokines tested more often than controls. The difference was statistically significant. CONCLUSION: The presence of mRNA encoding for IL-6, IL-1beta, IL-8, and TNFalpha is significantly detected by RT-PCR in vitreous and SRF samples of patients with PVR, indicating local production of these cytokines by vitreous and SRF cells.
Authors: A M Abu el-Asrar; J Van Damme; W Put; M Veckeneer; L Dralands; A Billiau; L Missotten Journal: Am J Ophthalmol Date: 1997-05 Impact factor: 5.258
Authors: L Smith-Thomas; J W Haycock; R Metcalfe; M Boulton; S Ellis; I G Rennie; P S Richardson; I Palmer; M A Parsons; S Mac Neil Journal: Curr Eye Res Date: 1998-08 Impact factor: 2.424
Authors: D J Kauffmann; J C van Meurs; D A Mertens; E Peperkamp; C Master; M E Gerritsen Journal: Invest Ophthalmol Vis Sci Date: 1994-03 Impact factor: 4.799
Authors: G A Limb; O Earley; S E Jones; F LeRoy; A H Chignell; D C Dumonde Journal: Graefes Arch Clin Exp Ophthalmol Date: 1994-11 Impact factor: 3.117
Authors: L Cabay; F Willermain; C Bruyns; J M Verdebout; Y Witta; J Baffi; T Velu; J Libert; L Caspers-Velu; A Maho; L Lespagnard Journal: Br J Ophthalmol Date: 2003-05 Impact factor: 4.638
Authors: J Troger; S Sellemond; G Kieselbach; M Kralinger; E Schmid; B Teuchner; Q A Nguyen; E Schretter-Irschick; W Göttinger Journal: Br J Ophthalmol Date: 2003-11 Impact factor: 4.638
Authors: Mi In Roh; Yusuke Murakami; Aristomenis Thanos; Demetrios G Vavvas; Joan W Miller Journal: Invest Ophthalmol Vis Sci Date: 2011-06-01 Impact factor: 4.799
Authors: I Fernandez-Bueno; M T Garcia-Gutierrez; G K Srivastava; M J Gayoso; J M Gonzalo-Orden; J C Pastor Journal: Mol Vis Date: 2013-04-17 Impact factor: 2.367